The biotech sector has consistently outperformed the overall stock market over the past half-decade. An increase in the amount of healthcare spending allocated to drugs, exiting new areas of drug development and robust M&A activity levels have produced a stellar performance from the biotech sector. The Biotech Forum offers compelling research for stock market investing in this lucrative sector.

When it comes to investing in biotech, I believe it is important to be diversified across this volatile and speculative area of the market maintaining a diversified portfolio.

Part of my investing strategy includes:

• Take small stakes in a variety of promising but speculative concerns.

• Balance portfolio with heavily weighted large-cap growth names with long-term earnings visibility selling at reasonable valuations.

“Strike-outs” is inevitable as drug discovery is a complex endeavor and most trials end in failure, however, just a couple of “grand slams” should lead to an outstanding overall performance in your portfolio over time.

It is this well-thought-out investing strategy that even with an acceptable amount of volatility has led to exceptional overall performance. I have personally benefitted from this strong performance in the biotech sector. My analysis of these hot biotech stocks over the past few years has resulted in substantial growth and created profits in my own portfolio. 

• Tired of missing out on huge small-cap biotech winners like Exelixis (EXEL), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN) & others? 

• Wonder which small biotech stocks scores of seasoned investors are talking about in our Live Chat community?

• Want a model-20 stock portfolio as well as some additional selections?

• Looking for exclusive investment analysis on attractive small-cap biotech stocks?

The Biotech Forum might be just the ticket for you!